Evidence map›Paper›PMID 42554873›Full record

ArticleEuropean journal of pediatrics2026

Clinical spectrum of pediatric patients carrying heterozygous MEFV gene variants.

Elif Erorhan, Pınar Özge Avar Aydın, Fatma Aydın, Onur Bahçeci, Doğacan Sarısoy, Büşra Tetik Dinçer, Özen Taş Aslan, Zeynep Birsin Özçakar

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Elif ErorhanDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0000-0002-8405-8378
Pınar Özge Avar AydınDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0000-0002-7469-109X
Fatma AydınDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0000-0003-0306-7473
Onur BahçeciDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0000-0002-2196-6440
Doğacan SarısoyDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0000-0002-2583-8948
Büşra Tetik DinçerDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0009-0003-9604-201X
Özen Taş AslanDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey.ORCID http://orcid.org/0000-0002-1132-8082
Zeynep Birsin ÖzçakarDepartment of Pediatrics, Division of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, 06590, Turkey. zbozcakar@yahoo.com.ORCID http://orcid.org/0000-0002-6376-9189

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The MEditerranean FeVer (MEFV) gene is a critical regulator of the innate immune response. The prototypical disease related to the MEFV gene is familial Mediterranean fever (FMF). Heterozygous MEFV gene variants have increasingly been reported in association with a wide range of inflammatory disorders besides FMF. The aim of this study was to evaluate the diagnostic spectrum and clinical and demographic findings of patients carrying heterozygous MEFV variants. This retrospective study included pediatric patients carrying heterozygous MEFV variants who were followed up at our center between January 2012 and January 2025. Diagnosis, demographics, and clinical manifestations were reviewed. A total of 270 patients with a median age of 7 years were identified. The diagnoses of the study population included FMF (67%), IgA vasculitis (7%), PFAPA syndrome (6%), inflammatory bowel disease (3%), juvenile idiopathic arthritis (3%), chronic nonbacterial osteomyelitis (2%), Behçet's disease (1%), and other vasculitides (1%). Fourteen percent of the patients were asymptomatic carriers. During follow-up, 22 of the 74 patients (30%) initially diagnosed with other inflammatory conditions later developed clinical features consistent with FMF. Colchicine therapy was initiated not only for typical attacks of FMF but also for selected indications in other inflammatory diseases.

conclusionHeterozygous MEFV variants have been reported to be associated with various inflammatory diseases besides FMF. Long-term follow-up is essential, as some patients may later develop FMF. MEFV gene testing should be considered in other inflammatory diseases with severe or atypical manifestations, particularly in populations where FMF is highly prevalent. WHAT IS KNOWN: •  Heterozygous MEFV variants have been associated with FMF and several inflammatory diseases. WHAT IS NEW: • This large pediatric cohort demonstrates that heterozygous MEFV variants may be encountered across a broad spectrum of inflammatory diseases, and some patients initially diagnosed with other conditions may subsequently develop FMF during follow-up.

Indexed as

Familial Mediterranean FeverPyrinAdolescentChildChild, PreschoolColchicineFemaleHeterozygoteHumansInfantMaleMutationRetrospective StudiesColchicineMEFV protein, humanPyrinAutoinflammationColchicineFamilial Mediterranean feverHeterozygoteMEFV gene

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.